ReviewInternal and emergency medicine2020
COVID-19, coagulopathy and venous thromboembolism: more questions than answers.
Review in Internal and emergency medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 109 citations in OpenAlex.
- Immunopathological syndromes: state of the art.Frontiers in medicine · 2025Review
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- Clinical characteristics and predictors of delayed discharge among children with SARS‑CoV‑2 Omicron variant infection.Biomedical reports · 2024Article
- Predictors of 2-year mortality in geriatric patients hospitalized with COVID-19 in Türkiye: a retrospective cohort study.Biomarkers in medicine · 2024Article
- Spectrum of Thrombotic Complications in Fatal Cases of COVID-19: Focus on Pulmonary Artery Thrombosis In Situ.Viruses · 2023Article
- High-flow nasal cannula therapy in patients with COVID-19 in intensive care units in a country with limited resources: a single-center experience.The Journal of international medical research · 2023Observational
- Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura.Hematology reports · 2023Article
- Treatment with prophylactic oral anticoagulants and the risk of mortality in COVID-19 patients: a nationwide cohort study.ERJ open research · 2023Article
- Clinical and functional status of patients with severe COVID-19 pneumonia: an observational study at 2-3 months following discharge.Frontiers in rehabilitation sciences · 2023Article
- Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2.International journal of molecular sciences · 2022Article
- Retinal Vascular Occlusion after COVID-19 Vaccination: More Coincidence than Causal Relationship? Data from a Retrospective Multicentre Study.Journal of clinical medicine · 2022Article
- COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review.Hematology reports · 2022Review
- Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.Inflammopharmacology · 2022Review
- Venous thromboembolism risk assessment of surgical patients in Southwest China using real-world data: establishment and evaluation of an improved venous thromboembolism risk model.BMC medical informatics and decision making · 2022Article
- Clinical outcomes of geriatric patients with COVID-19: review of one-year data.Aging clinical and experimental research · 2022Article
- How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.Frontiers in immunology · 2022Review
- Complete splenic infarction in association with COVID-19.BMJ case reports · 2021Article
- Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Central Retinal Vein Occlusion in patients with COVID-19 infection: A systematic review.Annals of medicine and surgery (2012) · 2021Review
- Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence.International journal of environmental research and public health · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. However, some relevant issues on the relationships between COVID-19, coagulopathy and VTE have yet to be fully elucidated. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? How do we frame the COVID-19 associated coagulopathy? Which role, if any, do antiphospolipid antibodies have? How do we tackle COVID-19 coagulopathy? In the complex scenario of an overwhelming pandemic, most everyday clinical decisions have to be taken without delay, although not yet supported by a sound scientific evidence. This review discusses the most recent findings of basic and clinical research about the COVID-associated coagulopathy, to foster a more thorough knowledge of the mechanisms underlying this compelling disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.